The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).
 
Elizabeth R Kessler
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Medivation/Astellas; Pfizer (Inst)
 
Junxiao Hu
No Relationships to Disclose
 
Geetika Srivastava
Consulting or Advisory Role - GlaxoSmithKline
 
Douglas Jerome Kemme
No Relationships to Disclose
 
Praveena Iruku
No Relationships to Disclose
 
Vishal Rana
Consulting or Advisory Role - Bayer; Seagen
 
Steven Robert Schuster
Speakers' Bureau - Pharmacyclics/Janssen
 
Mali Amirault
No Relationships to Disclose
 
Eryn Callihan
No Relationships to Disclose
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Elaine Tat Lam
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Advaxis (Inst); Amgen (Inst); Argos Therapeutics (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Constellation Pharmaceuticals (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Immunomedics (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Decibel Therapeutics